Stockreport

Pipeline Momentum Drives C4 Therapeutics Despite Q3 EPS Miss [Seeking Alpha]

C4 Therapeutics, Inc.  (CCCC) 
NASDAQ:AMEX Investor Relations: ir.chinacache.com
PDF CCCC's lead asset, cemsidomide, showed promising Phase 1 results in multiple myeloma and is advancing to pivotal Phase 2 and combination trials in 2026. Despite a net [Read more]